Filing identity and reporting period
The supplied filing is Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc. It is a Form 10-Q for the quarter ended September 30, 2022 (fiscal second quarter) and the six months then ended. The financial statements are unaudited.
Business context
Organovo is an early-stage biotechnology company developing 3D human tissue models, initially focused on inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Management reported advancing its first IBD model for Crohn’s disease to target discovery and validation. The company intends to use validated targets to develop drug candidates and pursue partnerships, licensing, or further development.
Key financial metrics
Amounts below are in millions of dollars except per-share data. The filing does not present a gross margin; reported revenue is royalty revenue and is small relative to operating expenses.
| Metric | Three months ended Sep. 30, 2022 | Three months ended Sep. 30, 2021 | Six months ended Sep. 30, 2022 | Six months ended Sep. 30, 2021 |
|---|---|---|---|---|
| Revenue | $0.077 | $0 | $0.077 | $0 |
| Research and development | $1.231 | $0.679 | $2.251 | $1.259 |
| Selling, general and administrative | $2.200 | $2.828 | $4.419 | $4.807 |
| Operating loss | $(3.354) | $(3.507) | $(6.593) | $(6.066) |
| Net loss | $(3.321) | $(3.505) | $(6.536) | $(6.037) |
| Net loss per share | $(0.38) | $(0.40) | $(0.75) | $(0.69) |
| Net cash used in operating activities | Not provided for quarter | Not provided for quarter | $(4.631) | $(3.556) |
At September 30, 2022, cash and cash equivalents were $13.265 million, short-term U.S. Treasury investments were $9.955 million, and restricted cash was $0.143 million. Current assets were $24.357 million, current liabilities $1.389 million, and working capital approximately $22.968 million. Total liabilities were $2.904 million, primarily operating lease liabilities; the filing reports no borrowings or other debt. Accumulated deficit was $314.275 million.
Changes versus prior comparable periods
- Quarterly net loss narrowed by $0.184 million, while six-month net loss increased by $0.499 million.
- R&D expense increased 81% for the quarter and 79% for the six-month period. Management attributed the increase to expanded research activity, staffing, laboratory costs, and facility costs; average R&D headcount rose to 15 for the quarter from 8 a year earlier.
- SG&A decreased 22% for the quarter and 8% for the six-month period, mainly because legal expenses fell after prior-year litigation was settled. Higher personnel and stock-based compensation partly offset the decline.
- Six-month operating cash use rose by $1.075 million year over year, primarily reflecting increased R&D activity. Cash, cash equivalents, and restricted cash declined $15.410 million, including substantial purchases of investments classified as investing cash flows.
Outlook, commentary, and risks
- Management forecast fiscal 2023 operating expenses of $12–$14 million and said available resources were expected to fund operations for at least 12 months from the reporting date. It also said additional capital will be needed to execute its longer-term plan; financing availability and terms are uncertain.
- The company recorded $0.077 million of sales-based royalty revenue under its February 2022 BICO Group license agreement. BICO’s $1.5 million nonrefundable upfront fee had been recognized in the prior quarter. The filing says complete and timely BICO sales reports were unavailable for July–September, so no revenue was recognized for that quarter’s royalty performance obligation because of the risk of a significant reversal. The reported $0.077 million is attributed to royalties earned through June 30.
- Management expects R&D staffing and activity to continue increasing, with associated expense growth. The company has no meaningful revenue base and expects substantial future losses.
- Principal risks include the unproven nature of its tissue-model and drug-discovery strategy, need for additional funding and potential shareholder dilution, dependence on reliable human-cell supplies and strategic partners, lengthy and uncertain drug development, patent challenges, and potential effects of COVID-19 and broader economic volatility.
- Prior BICO patent litigation and related proceedings were settled in February 2022. The company reported no accrual for legal contingencies, while noting that adverse resolutions could materially affect future-period financial statements. Management reported disclosure controls were effective and no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the filing issuer: this document identifies Organovo Holdings, Inc., not Vivosim Labs, Inc.
- Review the BICO royalty reporting and timing, including why no July–September royalty revenue was recognized and whether complete sales reports are subsequently received.
- Assess the assumptions behind management’s 12-month liquidity estimate, planned fiscal 2023 spending, and the company’s need and ability to raise further capital.
- Track evidence that the Crohn’s disease model produces validated drug targets and whether the company secures development or commercial partnerships.
- Consider potential dilution: the company had approximately $28.3 million of capacity remaining under its ATM program and $100 million available under its shelf registration, subject to applicable terms and market conditions.